Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?

Shares of Hims & Hers Health (NYSE: HIMS) skyrocketed after the telemedicine platform came to an agreement with Novo Nordisk (NYSE: NVO) to sell the drugmaker's popular GLP-1 weight loss drugs. The question on many investors' minds is whether it is too late to buy the stock. Let's take a closer look. Letting bygones be bygones Hims & Hers and Novo Nordisk have had a tumultuous relationship over the past couple of years. The companies formed a short-lived commercial partnership last year, only for Novo ...